July 29, 2024Future Oncology16 citationsOpen Access
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol.